Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TALIS BIOMEDICAL CORPORATION

(TLIS)
  Report
Delayed Quote. Delayed Nasdaq - 10/27 04:00:00 pm
4.99 USD   -5.67%
10/26Talis Biomedical to Announce Third Quarter 2021 Financial Results on November 15, 2021
AQ
09/28NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/27Top Midday Decliners
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

The Law Offices of Frank R. Cruz : Continues Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

09/09/2021 | 03:16pm EDT

The Law Offices of Frank R. Cruz continues its investigation of Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On August 10, 2021, Talis reported its second quarter 2021 financial results. During the related conference call, the Company revealed that its “development timelines have been extended by delays in the launching of [Talis’] COVID-19 test and manufacturing scale.”

On this news, the Company’s stock price fell $0.58, or 6%, to close at $8.39 per share on August 11, 2021, thereby injuring investors.

Then, on August 30, 2021, after the market closed, Talis announced that its Chief Executive Officer, Brian Coe, had “stepped down.”

On this news, the Company’s stock price fell $1.00, or 11%, to close at $8.06 per share on August 31, 2021, thereby injuring investors further.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Talis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


ę Business Wire 2021
All news about TALIS BIOMEDICAL CORPORATION
10/26Talis Biomedical to Announce Third Quarter 2021 Financial Results on November 15, 2021
AQ
09/28NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/27Top Midday Decliners
MT
09/27TALIS BIOMEDICAL : JPMorgan Downgrades Talis Biomedical to Underweight From Neutral, Cuts ..
MT
09/14GLANCY PRONGAY & MURRAY LLP : a National Class Action Law Firm, Continues Investigation of..
BU
09/14INVESTOR ALERT : Law Offices of Howard G. Smith Continues Investigation of Talis Biomedica..
BU
09/13TALIS ALERT : Bragar Eagel & Squire, P.C. is Investigating Talis on Behalf of Talis Stockh..
BU
09/09GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces Investigation..
BU
09/09THE LAW OFFICES OF FRANK R. CRUZ : Continues Investigation of Talis Biomedical Corporation..
BU
08/31THE LAW OFFICES OF FRANK R. CRUZ : Announces Investigation of Talis Biomedical Corporation..
BU
More news
Analyst Recommendations on TALIS BIOMEDICAL CORPORATION
More recommendations
Financials (USD)
Sales 2021 10,6 M - -
Net income 2021 -188 M - -
Net cash 2021 263 M - -
P/E ratio 2021 -0,53x
Yield 2021 -
Capitalization 128 M 128 M -
EV / Sales 2021 -12,7x
EV / Sales 2022 -0,92x
Nbr of Employees 135
Free-Float 98,0%
Chart TALIS BIOMEDICAL CORPORATION
Duration : Period :
Talis Biomedical Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TALIS BIOMEDICAL CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 4,99 $
Average target price 7,00 $
Spread / Average Target 40,3%
EPS Revisions
Managers and Directors
Kimberly J. Popovits Chief Executive Officer & Director
John Roger Moody Chief Financial Officer
Felix James Baker Chairman
Ramesh Ramakrishnan Senior Vice President-Research & Development
Liang Li Director-Technology & Strategy
Sector and Competitors
1st jan.Capi. (M$)
TALIS BIOMEDICAL CORPORATION0.00%128
MODERNA, INC.226.29%137 595
LONZA GROUP AG32.74%61 065
IQVIA HOLDINGS INC.41.93%48 579
SEAGEN INC.-0.30%31 768
CELLTRION, INC.-39.00%25 528